Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Genentech"

21 News Found

Roche’s US subsidiary Genentech breaks ground on $700 million manufacturing facility in North Carolina
News | August 26, 2025

Roche’s US subsidiary Genentech breaks ground on $700 million manufacturing facility in North Carolina

The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D


USFDA approves Genentech’s Vabysmo to treat causes of vision loss
Drug Approval | January 31, 2022

USFDA approves Genentech’s Vabysmo to treat causes of vision loss

Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need


Drug Hunter secures seed investment to scale drug discovery knowledge platform
R&D | September 16, 2025

Drug Hunter secures seed investment to scale drug discovery knowledge platform

Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management


Roche appoints Wafaa Mamilli as Chief Digital Technology Officer
People | January 30, 2025

Roche appoints Wafaa Mamilli as Chief Digital Technology Officer

Mamilli last held the role of Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health at Zoetis


Gilead Sciences appoints Dietmar Berger as Chief Medical Officer
People | December 14, 2024

Gilead Sciences appoints Dietmar Berger as Chief Medical Officer

Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines


Lonza reports softer performance in Q1 2024
News | May 14, 2024

Lonza reports softer performance in Q1 2024

Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s


Lonza to buy US biologics site from Roche for US$ 1.2 billion
Biotech | March 20, 2024

Lonza to buy US biologics site from Roche for US$ 1.2 billion

Lonza plans to invest approximately CHF 500 million to upgrade the facility


New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions with food allergies
Diagnostic Center | February 28, 2024

New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions with food allergies

The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies


AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study
Diagnostic Center | January 31, 2024

AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study

About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation


Roche receives USFDA’s priority review to Xolair for food allergies based on positive NIH Phase III study results
Drug Approval | December 26, 2023

Roche receives USFDA’s priority review to Xolair for food allergies based on positive NIH Phase III study results

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure